Glaukos rise as US FDA clears eye therapy for rare corneal disease

Glaukos

20/10/2025 12:49

** Shares of medtech firm Glaukos GKOS.N rise 3% to $89.48 premarket

** Co gets U.S. FDA approval for Epioxa, a topical eye therapy for keratoconus; drug to launch in Q1 2026

** Keratoconus is a rare eye disease that thins and weakens the cornea

** Epioxa is the first FDA-approved therapy that avoids painful removal of the cornea's outer layer - GKOS

** GKOS says approval backed by two late-stage trials involving over 400 patients; met main goals with good safety

** Keratoconus affects mostly people under 30 and can lead to blindness if untreated, co says

** Up to last close, stock down ~42% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.pandey@thomsonreuters.com))